In summary, given the global immune suppressive nature of human tumor-derived sMIC and the cancer therapeutic potential of the IL-15 superagonist complex ALT-803, which is currently in clinical trials to treat advanced malignancies, our findings provide the rationale for combination therapy of an antibody targeting sMIC and ALT-803 to improve clinical outcomes. The gene discussed is IL15; the disease is cancer.